ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

PTLA Portola Pharmaceuticals Inc

18.03
0.00 (0.00%)
06 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Portola Pharmaceuticals Inc NASDAQ:PTLA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 18.03 18.00 18.10 0 01:00:00

Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020

12/02/2020 1:00pm

PR Newswire (US)


Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Portola Pharmaceuticals Charts.

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the fourth quarter and full year ended December 31, 2019, and provide a general business overview, on Wednesday, February 26, 2020, at 4:30 p.m. ET (1:30 p.m. PT).

Portola Pharmaceuticals, Inc. Logo (PRNewsfoto/Portola Pharmaceuticals, Inc.®)

Conference Call Details
The live conference call on Wednesday, February 26, 2020, at 4:30 p.m. ET, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 6192918. The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com. It will be archived for 30 days following the call.

About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/portola-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2019-financial-results-on-wednesday-february-26-2020-301003228.html

SOURCE Portola Pharmaceuticals, Inc.®

Copyright 2020 PR Newswire

1 Year Portola Pharmaceuticals Chart

1 Year Portola Pharmaceuticals Chart

1 Month Portola Pharmaceuticals Chart

1 Month Portola Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock